236 related articles for article (PubMed ID: 34256606)
41. Evaluation of Concurrent Oral and Long-Acting Injectable Antipsychotic Prescribing at the Minneapolis Veterans Affairs Health Care System.
Dimitropoulos E; Drogemuller L; Wong K
J Clin Psychopharmacol; 2017 Oct; 37(5):605-608. PubMed ID: 28816923
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE
J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329
[TBL] [Abstract][Full Text] [Related]
43. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Soares-Weiser K; Béchard-Evans L; Lawson AH; Davis J; Ascher-Svanum H
Eur Neuropsychopharmacol; 2013 Feb; 23(2):118-25. PubMed ID: 22633617
[TBL] [Abstract][Full Text] [Related]
44. Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia.
Mohamed S; Rosenheck R; Harpaz-Rotem I; Leslie D; Sernyak MJ
Psychiatr Q; 2009 Dec; 80(4):241-9. PubMed ID: 19768543
[TBL] [Abstract][Full Text] [Related]
45. Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia.
Detke HC; Weiden PJ; Llorca PM; Choukour M; Watson SB; Brunner E; Ascher-Svanum H
J Clin Psychopharmacol; 2014 Aug; 34(4):426-34. PubMed ID: 24781441
[TBL] [Abstract][Full Text] [Related]
46. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed.
Meyer JM
CNS Spectr; 2017 Dec; 22(S1):14-28. PubMed ID: 29350127
[TBL] [Abstract][Full Text] [Related]
47. A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review.
Kishi T; Citrome L; Sakuma K; Iwata N
Psychiatry Res; 2024 Mar; 333():115761. PubMed ID: 38301289
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
49. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
[No Abstract] [Full Text] [Related]
50. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
[TBL] [Abstract][Full Text] [Related]
51. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Rosenheck RA; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
Am J Psychiatry; 2006 Apr; 163(4):611-22. PubMed ID: 16585435
[TBL] [Abstract][Full Text] [Related]
52. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
[TBL] [Abstract][Full Text] [Related]
53. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders.
Boyer L; Falissard B; Nuss P; Collin C; Duret S; Rabbani M; De Chefdebien I; Tonelli I; Llorca PM; Fond G
Mol Psychiatry; 2023 Sep; 28(9):3709-3716. PubMed ID: 37479781
[TBL] [Abstract][Full Text] [Related]
54. Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: Systematic review and network meta-analysis.
Wang D; Schneider-Thoma J; Siafis S; Qin M; Wu H; Zhu Y; Davis JM; Priller J; Leucht S
Eur Neuropsychopharmacol; 2024 Jun; 83():11-18. PubMed ID: 38490016
[TBL] [Abstract][Full Text] [Related]
55. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
Barnett PG; Scott JY; Krystal JH; Rosenheck RA;
J Clin Psychiatry; 2012 May; 73(5):696-702. PubMed ID: 22697193
[TBL] [Abstract][Full Text] [Related]
56. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
Lin D; Thompson-Leduc P; Ghelerter I; Nguyen H; Lafeuille MH; Benson C; Mavros P; Lefebvre P
CNS Drugs; 2021 May; 35(5):469-481. PubMed ID: 33909272
[TBL] [Abstract][Full Text] [Related]
57. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
58. Predictors of discontinuation and hospitalization during long-acting injectable antipsychotic treatment in patients with schizophrenia spectrum disorder.
Üçok A; Yağcioğlu EA; Aydin M; Kara İA; Erbasan V; Türkoğlu Ö; Ergün S; Chousein MG; Oktar N; Uçar N; Köroğlu BS; Ozan E
Int Clin Psychopharmacol; 2021 Mar; 36(2):89-96. PubMed ID: 33512962
[TBL] [Abstract][Full Text] [Related]
59. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
Katona L; Czobor P; Bitter I
Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583
[TBL] [Abstract][Full Text] [Related]
60. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
Rosa F; Schreiner A; Thomas P; Sherif T
Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
